Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Update

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 101,413 shares, a drop of 70.0% from the June 15th total of 337,919 shares. Approximately 8.3% of the company’s shares are short sold. Based on an average daily volume of 158,411 shares, the days-to-cover ratio is currently 0.6 days.

Aspire Biopharma Stock Down 2.3%

ASBP traded down $0.14 during midday trading on Monday, hitting $5.87. 28,115 shares of the company were exchanged, compared to its average volume of 405,103. The firm’s 50 day moving average price is $5.73 and its 200-day moving average price is $36.30. Aspire Biopharma has a 1-year low of $3.31 and a 1-year high of $1,050.36. The firm has a market capitalization of $7.60 million, a P/E ratio of -0.05 and a beta of 0.15.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings data on Friday, May 15th. The company reported ($20.57) EPS for the quarter. The company had revenue of $0.03 million during the quarter.

Hedge Funds Weigh In On Aspire Biopharma

Institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd increased its stake in Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after purchasing an additional 237,620 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Aspire Biopharma by 625.8% during the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after purchasing an additional 131,533 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Aspire Biopharma during the 3rd quarter worth about $28,000. 19.17% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.